<- Go Home

BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Market Cap

AUD 213.9M

Volume

360.6K

Cash and Equivalents

AUD 7.6M

EBITDA

AUD 10.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 19.7M

Profit Margin

41.05%

52 Week High

AUD 1.10

52 Week Low

AUD 0.33

Dividend

N/A

Price / Book Value

10.26

Price / Earnings

23.43

Price / Tangible Book Value

10.43

Enterprise Value

AUD 211.6M

Enterprise Value / EBITDA

19.90

Operating Income

AUD 9.9M

Return on Equity

66.14%

Return on Assets

24.99

Cash and Short Term Investments

AUD 7.6M

Debt

AUD 5.4M

Equity

AUD 20.2M

Revenue

AUD 48.0M

Unlevered FCF

-AUD 2.3M

Sector

Life Sciences Tools and Services

Category

N/A

Company Stock Pitches